Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to -$5.7 million.

  • iBio's Free Cash Flow fell 4724.65% to -$5.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$19.2 million, marking a year-over-year decrease of 1715.86%. This contributed to the annual value of -$15.3 million for FY2025, which is 1855.4% up from last year.
  • Per iBio's latest filing, its Free Cash Flow stood at -$5.7 million for Q4 2025, which was down 4724.65% from -$5.7 million recorded in Q3 2025.
  • iBio's Free Cash Flow's 5-year high stood at -$3.1 million during Q1 2025, with a 5-year trough of -$16.4 million in Q3 2022.
  • In the last 5 years, iBio's Free Cash Flow had a median value of -$5.6 million in 2023 and averaged -$7.2 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 11639.43% in 2021, then skyrocketed by 6751.43% in 2023.
  • Over the past 5 years, iBio's Free Cash Flow (Quarter) stood at -$12.8 million in 2021, then grew by 17.4% to -$10.6 million in 2022, then skyrocketed by 55.56% to -$4.7 million in 2023, then grew by 17.42% to -$3.9 million in 2024, then crashed by 47.25% to -$5.7 million in 2025.
  • Its last three reported values are -$5.7 million in Q4 2025, -$5.7 million for Q3 2025, and -$4.6 million during Q2 2025.